Weekly influenza update, week 9, March 2018

Data Infographic Map

Influenza continues to circulate widely in the region and some eastern European countries are experiencing a slow start. Countries experiencing a cold spell may experience a more severe season. Overall, 49% of individuals sampled from primary healthcare settings tested positive for influenza virus, a slight decrease compared to the previous week (50%). Both influenza virus types A and B were co-circulating with a higher proportion of type B viruses. Differences in proportions of circulating influenza virus types and A subtypes were observed between countries.The majority of severe cases admitted to non-ICU hospital wards were adults infected by influenza type B viruses. Half of the severe cases admitted to ICU were adults infected by influenza type A viruses. Based on data provided by 17 EU countries to EuroMOMO, excess mortality from all causes has been raised significantly over past months in the south-western part of the European region, notably in the elderly. However, mortality seems to be declining.

Infographic displaying data from influenza in Europe report

Download

Thumbnail
flu-infographic_2018_week9 - EN - [PNG-98.67 KB]

2017/18 season overview 

  • For the region overall, a higher proportion of type B compared to type A viruses has been detected in sentinel and non-sentinel sources, representing a high level of circulation of influenza B viruses compared with recent seasons. Of the type A virus detections from sentinel sources, the majority of which were subtyped, A(H1N1)pdm09 viruses have outnumbered A(H3N2) viruses. In non-sentinel sources, more A(H3N2) viruses were reported than A(H1N1)pdm09 viruses.
  • The majority of severe cases reported this season are due to influenza B and occur in persons above the age of 15 years. For laboratory-confirmed influenza cases in ICU, comparable numbers were infected by influenza type A and B viruses, and the elderly were at increased risk of ICU admission. In laboratory-confirmed influenza cases reported from wards other than ICU, type B viruses were detected approximately twice as frequently as type A viruses.
  • For type B viruses from both sentinel and non-sentinel sources, B/Yamagata lineage viruses have greatly outnumbered those of the B/Victoria lineage. The current trivalent seasonal influenza vaccine does not include a virus from the B/Yamagata lineage.
  • Different patterns of dominant type and A subtypes were observed between the countries of the Region, which may be due to differences in relative weights of information being derived from sentinel, non-sentinel and severe influenza case sources of information.
  • While low in number, 60% of the genetically characterized A(H3N2) viruses belong to clade 3C.2a, the clade of the vaccine virus described in the WHO recommendations for vaccine composition for the northern hemisphere 2017–2018, and 37% to subclade 3C.2a1, with mammalian cell-cultured viruses in both clades being antigenically similar.
  • Although few B/Victoria lineage viruses have been detected, their characterization has shown an increasing percentage (currently 47%) of viruses belonging to a subclade of clade 1A viruses, represented by B/Norway/2409/2017. These viruses have a two amino acid deletion in haemagglutinin (Δ162-163) and are antigenically different from the current trivalent vaccine component, a B/Brisbane/60/2008-like virus.
  • Interim results from 5 European studies indicate that, in all age groups, influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, 7 to 42% against influenza A(H3N2) and 36 to 54% against influenza B, which is consistent with previous estimates from CanadaFinlandGermanySpain, Stockholm County and the United States of America.
  • Additional information on global influenza activity is available from WHO’s biweekly global updates.
  • From 19–21 February 2018, WHO-HQ held the Vaccine Composition Meeting during which recommendations were made for the composition of the 2018–2019 northern hemisphere vaccine. The full report is available here.